A US congressional committee has voted in favour of providing innovative biologic drug manufacturers with 12 years of data exclusivity for their products as part of ongoing efforts to establish a regulatory framework for the approval of biosimilars. It has also supported blocking pay-for-delay deals between brand-name and generic pharmaceutical companies...
Please login to read the full article.
